Quince Therapeutics SpA

Research, Red blood cell, Biotech, Platform, Rare disease
Founded in 2007
Bresso, Lombardia
None

About Quince Therapeutics SpA

EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the "Most Innovative StartUp Italia Award" chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient's own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 32.4M None
  • Last Funding: 32.4M None (None)
  • Funding Status: None

Technology Stack

Quince Therapeutics SpA actively uses None products in their tech stack.

Market Presence

Industries: Research, Red blood cell, Biotech, Platform, Rare disease

Headquarters: Bresso, Lombardia